Logo image
Chronic antithrombotic therapy in post-myocardial infarction patients
Journal article   Peer reviewed

Chronic antithrombotic therapy in post-myocardial infarction patients

Sandeep Sodhi, Robert Lee and Michael Ezekowitz
Clinics in geriatric medicine, v 22(1)
Feb 2006
PMID: 16377473

Abstract

Aged Aged, 80 and over Dose-Response Relationship, Drug Drug Administration Schedule Female Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use Follow-Up Studies Geriatric Assessment Humans Long-Term Care Male Monitoring, Physiologic - methods Myocardial Infarction - diagnosis Myocardial Infarction - drug therapy Myocardial Infarction - mortality Randomized Controlled Trials as Topic Risk Assessment Severity of Illness Index Survival Analysis Treatment Outcome
Recent advances in the acute treatment of myocardial infarction (MI) have allowed more to survive the initial event in coronary artery disease. Increasing importance has been placed on secondary-prevention strategies, with more attention directed toward an optimal therapeutic regimen for post-MI patients. When it comes to the subpopulation of the elderly who have had an MI, however, current practice relies less on population-specific evidence and more on extrapolation of current data. This article reviews the pathogenesis of coronary heart disease and MI, and highlights recent major trials that have explored antiplatelet and anticoagulant medications in the chronic treatment of the post-MI population. Special consideration is given to the geriatric community and its unique challenge regarding chronic antithrombotic therapy.

Metrics

5 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Geriatrics & Gerontology
Logo image